FDA approves new treatment for rare type of pancreatic cancer May 6, 2011

On Thursday, the U.S. Food and Drug Administration approved Afinitor (everolimus) to treat patients with progressive neuroendocrine tumors located in the pancreas (PNET) that cannot be removed by surgery or that have spread to other parts of the body (metastatic). Neuroendocrine tumors found in the pancreas are slow-growing and rare.                                                                                                      Afinitor is marketed by East Hanover, N.J.-based Novartis.

FOR THE FULL NEWS VISITE :

: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254350.htm